Literature DB >> 9571146

Fluvastatin enhances receptor-stimulated intracellular Ca2+ release in human keratinocytes.

K D Coutant1, B Wolff-Winiski, N S Ryder.   

Abstract

We analyzed the effect of isoprenoid depletion by fluvastatin on bradykinin (BK)- and epidermal growth factor (EGF)-mediated Ca2+ mobilization and prostaglandin E2 production, in the human keratinocyte cell line HaCaT. BK and EGF stimulated Ca2+ mobilization in an agonist-dependent manner. The synthesis of prostaglandin E2 paralleled the level of Ca2+ mobilization induced by BK and EGF. Treatment with fluvastatin increased the EGF-promoted but not the BK-promoted Ca2+ mobilization and prostaglandin E2 production in Ca(2+)-containing medium. In the absence of extracellular Ca2+, fluvastatin treatment led to an increase in intracellular Ca2+ release by both agonists. This effect was abolished by depleting the intracellular pool of Ca2+ with thapsigargin. Our findings showed that the intracellular Ca2+ release was dependent on the metabolism of mevalonate and that the Ca2+ mobilization modulated prostaglandin E2 synthesis in human keratinocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571146     DOI: 10.1006/bbrc.1998.8429

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Role of prostaglandin pathway and alendronate-based carriers to enhance statin-induced bone.

Authors:  Yeonju Lee; Xinming Liu; Ali Nawshad; David B Marx; Dong Wang; Richard A Reinhardt
Journal:  Mol Pharm       Date:  2011-04-05       Impact factor: 4.939

2.  B1 and B2 kinin receptor blockade improves psoriasis-like disease.

Authors:  Bruna da Silva Soley; Leonardo Martins Silva; Daniel Augusto Gasparin Bueno Mendes; André Báfica; João Bosco Pesquero; Michael Bader; Deborah A Witherden; Wendy L Havran; João B Calixto; Michel Fleith Otuki; Daniela Almeida Cabrini
Journal:  Br J Pharmacol       Date:  2020-05-30       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.